Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Licenses Immunology Drugs for Up to $880 Million

By Brian Orelli, PhD - Mar 31, 2020 at 2:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharma giant will develop and market up to four drugs from the pipeline of privately-held Sitryx.

Eli Lilly (LLY -1.46%) is boosting its pipeline through a deal with privately held Sitryx, a company focused on developing drugs that could treat cancer and inflammatory diseases by regulating the metabolism of immune cells.

All of Sitryx's projects are still in the preclinical stage. The company was founded in 2018 by a group of well-known immunology researchers, and GlaxoSmithKline (GSK -0.07%) contributed some technology and other assistance as well.

"Regulating the metabolism of immune cells is a promising approach to treating these diseases, and we look forward to working with the talented researchers at Sitryx to advance their novel immunometabolism targets," Ajay Nirula, vice president of immunology at Eli Lilly, said in a statement.

Scientist working in a lab

Image source: Getty Images.

Sitryx and Eli Lilly will undertake a five-year research collaboration with the goal of developing four drugs. The pharma giant has already picked Sitryx's two lead projects as the first two drugs to license. Sitryx will be responsible for drug discovery, while Eli Lilly will pay for and manage their clinical development and marketing.

Eli Lilly is paying Sitryx $50 million up front and making a $10 million equity investment in the company. Sitryx is eligible for up to $820 million for reaching development milestones, and could also get commercialization milestones and royalties in the mid- to high-single-digit percentage range if the drugs from the collaboration are eventually approved by regulators.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$301.32 (-1.46%) $-4.47
GSK Stock Quote
GSK
GSK
$40.57 (-0.07%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.